A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

Trial Details

NCT ID

NCT07053670

Phase

PHASE1

Sponsor

Tongji Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• CAR T cells

Locations (sample)

• Wuhang, Hubei, China

Key Eligibility Criteria

• Participants must voluntarily sign the informed consent form (ICF) and must be willing and be able to adhere to the study visit schedule and other …
• 18-75 years old;
• Histologically or cytologically confirmed B-NHL, according the 5th edition of the WHO classification of haematolymphoid tumours, including:
• 1\) Cohort A1: Large B-cell lymphoma, including diffuse large B-cell lymphoma not other specified (DLBCL, NOS), primary mediastinal large B-cell ly…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.